Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma ; volume:10 ; number:1 ; day:15 ; month:4 ; year:2024 ; pages:1-13 ; date:12.2024
Cell death discovery ; 10, Heft 1 (15.4.2024), 1-13, 12.2024
- Creator
-
Cavallo, Maria R.
Yo, Jacob C.
Gallant, Kayla C.
Cunanan, Camille J.
Amirfallah, Amirali
Daniali, Marzieh
Sanders, Alyssa B.
Aplin, Andrew E.
Pribitkin, Edmund A.
Hartsough, Edward J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41420-024-01945-0
- URN
-
urn:nbn:de:101:1-2406272114298.006565431694
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cavallo, Maria R.
- Yo, Jacob C.
- Gallant, Kayla C.
- Cunanan, Camille J.
- Amirfallah, Amirali
- Daniali, Marzieh
- Sanders, Alyssa B.
- Aplin, Andrew E.
- Pribitkin, Edmund A.
- Hartsough, Edward J.
- SpringerLink (Online service)
Other Objects (12)
Phospho-proteomic analysis of B-Raf complexes
Mutationsscreening von A-Raf und B-Raf in humanen Glioblastom-Tumorproben
B-Raf specific antibody responses in melanoma patients
B-Raf and the inhibitors: from bench to bedside
MCL.
Functional analysis of the B-raf and raf-1 proto oncogenes in B lymphocytes
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf
BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation
Phospho-proteomic analysis of B-Raf complexes
Mutationsscreening von A-Raf und B-Raf in humanen Glioblastom-Tumorproben
B-Raf specific antibody responses in melanoma patients
B-Raf and the inhibitors: from bench to bedside
MCL.
Functional analysis of the B-raf and raf-1 proto oncogenes in B lymphocytes
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf
BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation
Phospho-proteomic analysis of B-Raf complexes
Mutationsscreening von A-Raf und B-Raf in humanen Glioblastom-Tumorproben
B-Raf specific antibody responses in melanoma patients
B-Raf and the inhibitors: from bench to bedside
MCL.
Functional analysis of the B-raf and raf-1 proto oncogenes in B lymphocytes
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf
BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor